M&A Deal Summary |
|
---|---|
Date | 2021-03-24 |
Target | Trapelo Health |
Sector | Information Services |
Buyer(s) | NeoGenomics |
Deal Type | Add-on Acquisition |
Deal Value | 65M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2001 |
Sector | Life Science |
Employees | 2,100 |
Revenue | 592M USD (2023) |
NeoGenomics is a clinical laboratory that specializes in cancer genetics diagnostic testing. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. NeoGenomics was founded in 2001 and is based in Fort Myers, Florida.
DEAL STATS | # |
---|---|
Overall | 4 of 6 |
Sector (Information Services) | 1 of 1 |
Type (Add-on Acquisition) | 3 of 5 |
State (Michigan) | 1 of 1 |
Country (United States) | 4 of 4 |
Year (2021) | 1 of 3 |
Size (of disclosed) | 4 of 5 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2018-10-23 |
Genoptix
Carlsbad, California, United States Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California. |
Buy | $126M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-05-05 |
Inivata
Cambridge, United Kingdom Inivata is a liquid biopsy company with its InVision platform that unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response, and detect relapse. Inivata's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst-Lung is commercially available internationally and through NeoGenomics in the US. It offers competitive sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR assay - allowing the highly sensitive detection of residual disease and recurrence - which has been granted Breakthrough Device Designation by the US FDA. |
Buy | $390M |